These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34050856)

  • 1. Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
    O'Dor SL; Washburn J; Howard KR; Reinecke MA
    Res Child Adolesc Psychopathol; 2021 Nov; 49(11):1489-1501. PubMed ID: 34050856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
    March J; Silva S; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1393-403. PubMed ID: 17135984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for Adolescents with Depression Study (TADS): safety results.
    Emslie G; Kratochvil C; Vitiello B; Silva S; Mayes T; McNulty S; Weller E; Waslick B; Casat C; Walkup J; Pathak S; Rohde P; Posner K; March J; ;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1440-55. PubMed ID: 17135989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating patient-specific treatment advantages in the 'Treatment for Adolescents with Depression Study'.
    Foster S; Mohler-Kuo M; Tay L; Hothorn T; Seibold H
    J Psychiatr Res; 2019 May; 112():61-70. PubMed ID: 30856378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
    Rohde P; Silva SG; Tonev ST; Kennard BD; Vitiello B; Kratochvil CJ; Reinecke MA; Curry JF; Simons AD; March JS
    Arch Gen Psychiatry; 2008 Apr; 65(4):447-55. PubMed ID: 18391133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
    Kratochvil C; Emslie G; Silva S; McNulty S; Walkup J; Curry J; Reinecke M; Vitiello B; Rohde P; Feeny N; Casat C; Pathak S; Weller E; May D; Mayes T; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1412-8. PubMed ID: 17135986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
    Lewis CC; Simons AD; Nguyen LJ; Murakami JL; Reid MW; Silva SG; March JS
    J Am Acad Child Adolesc Psychiatry; 2010 Feb; 49(2):132-40. PubMed ID: 20215935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
    Vitiello B; Rohde P; Silva S; Wells K; Casat C; Waslick B; Simons A; Reinecke M; Weller E; Kratochvil C; Walkup J; Pathak S; Robins M; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1419-26. PubMed ID: 17135987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
    Kratochvil CJ; May DE; Silva SG; Madaan V; Puumala SE; Curry JF; Walkup J; Kepley H; Vitiello B; March JS
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):519-27. PubMed ID: 19877976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
    Scott K; Lewis CC; Marti CN
    J Am Acad Child Adolesc Psychiatry; 2019 Mar; 58(3):319-328. PubMed ID: 30768414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of alcohol or substance use disorders following treatment for adolescent depression.
    Curry J; Silva S; Rohde P; Ginsburg G; Kennard B; Kratochvil C; Simons A; Kirchner J; May D; Mayes T; Feeny N; Albano AM; Lavanier S; Reinecke M; Jacobs R; Becker-Weidman E; Weller E; Emslie G; Walkup J; Kastelic E; Burns B; Wells K; March J
    J Consult Clin Psychol; 2012 Apr; 80(2):299-312. PubMed ID: 22250853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating a broader range of depressed adolescents with combined therapy.
    Foster S; Mohler-Kuo M
    J Affect Disord; 2018 Dec; 241():417-424. PubMed ID: 30145512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a data-driven algorithm for guiding selection between cognitive behavioral therapy, fluoxetine, and combination treatment for adolescent depression.
    Gunlicks-Stoessel M; Klimes-Dougan B; VanZomeren A; Ma S
    Transl Psychiatry; 2020 Sep; 10(1):321. PubMed ID: 32958758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
    Kennard BD; Emslie GJ; Mayes TL; Nakonezny PA; Jones JM; Foxwell AA; King J
    Am J Psychiatry; 2014 Oct; 171(10):1083-90. PubMed ID: 24935082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS).
    Jacobs RH; Reinecke MA; Gollan JK; Jordan N; Silva SG; March JS
    Behav Res Ther; 2010 Nov; 48(11):1155-9. PubMed ID: 20843506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.